Moderna bullish on programs beyond COVID as AstraZeneca hands back another prospect Regeneron scratches NGF inhibitor and cat allergy therapy from pipeline Sarepta preps $1.2B war chest as DMD gene therapy nears accelerated FDA nod The eagles have landed: GSK halts successful UTI trials early, preps FDA submission Gilead, Arcus slim phase 3 TIGIT trial to take on king Keytruda More biotechs hit the wall as Rubius lays off 82% of staff and Tricida seeks a sale Emalex wants to fill gaps in 'exceptionally difficult' Tourette syndrome with massive $250M raise Kura snags up to $150M from Bristol Myers, VC Hercules to fund operations through 2026 J.P. Morgan's new life sciences private equity arm will be hottest ticket at firm's upcoming conference | 